Close X
Saturday, September 21, 2024
ADVT 
International

WHO worried about surge of COVID in China amid lack of info

Darpan News Desk The Canadian Press, 04 Jan, 2023 12:07 PM
  • WHO worried about surge of COVID in China amid lack of info

GENEVA (AP) — The head of the World Health Organization said Wednesday the agency is “concerned about the risk to life in China” amid the coronavirus’ explosive spread across the country and the lack of outbreak data from the Chinese government.

WHO Director-General Tedros Adhanom Ghebreyesus said the agency recently met with Chinese officials to underline the importance of sharing more details about COVID-19 issues including hospitalization rates and genetic sequences, even as the pandemic continues to recede globally since it began in late 2019.

“Data remains essential for WHO to carry out regular, rapid and robust risk assessments of the global situation,” Tedros said at a press briefing.

Tedros said he understood why numerous countries have recently taken measures against travelers coming from China, saying “it’s understandable that some countries are taking steps to prevent their citizens” given the void of information about COVID-19.

WHO emergencies chief Dr. Michael Ryan said the testing protocols implemented by some countries were not a restriction against travel.

“It's not an excessive measure based on individual countries' risk assessment,” Ryan said.

He noted that for the past three years, China has had some of the world's harshest rules regarding COVID-19. “The reality for China is that many countries (now feel) they don’t have enough information to base their risk assessment,” he said.

Earlier this week, Chinese officials sharply criticized COVID-19 testing requirements imposed on visitors from China and threatened countermeasures against countries involved, which include the U.S. and several European nations.

“We believe that the entry restrictions adopted by some countries targeting China lack scientific basis, and some excessive practices are even more unacceptable,” Foreign Ministry spokesperson Mao Ning said at a briefing Tuesday.

The WHO's Ryan added that there were continuing concerns about how Chinese officials are recording coronavirus deaths, saying that their definition, which only counts COVID-19 deaths if there is a record of respiratory failure, is too narrow.

Throughout December, China recorded only 13 official COVID-19 deaths, despite many thousands of cases every day and reports about overwhelmed hospitals, fever clinics and crematoriums.

A WHO expert group said Wednesday that no worrying new COVID variants have been identified in China based on the information authorities have shared, including genetic sequences deposited into a public database. The WHO said Chinese scientists have now shared more than 770 sequences, with omicron subvariants BA.5 and its descendants accounting for more than 97% of all local infections. Globally, BA.5 variants comprise about 68% of all sequences.

The European Centre for Disease Prevention and Control said it did not expect the surge of COVID-19 in China to affect the outbreak in Europe, given the high rates of vaccination across the continent. It also noted that the variants spreading in China were already present in Europe, suggesting that any spillover from China would have a negligible impact.

Maria Van Kerkhove, the WHO’s technical lead on COVID-19, said the agency was currently evaluating the significance of the variant known as XBB.1.5, which has recently comprised an increasing proportion of cases in the U.S.

“Our concern is how transmissible it is,” Van Kerkhove said. “The more this virus circulates, the more chances it will have to change,” she said, adding that further waves of transmission do not necessarily have to translate into more deaths, with the wide availability of vaccination and drugs.

Van Kerkhove said there is no data yet to prove that XBB.1.5 causes more severe disease, but that the WHO is working on a new risk assessment of the variant that it expects to release soon.

___

Follow AP’s coverage of the pandemic at https://apnews.com/hub/coronavirus-pandemic

MORE International ARTICLES

AstraZeneca resuming US testing of COVID-19 vaccine

AstraZeneca resuming US testing of COVID-19 vaccine
The AstraZenca vaccine, developed with Oxford University, is one of several coronavirus vaccine candidates in final-stage testing around the world.

AstraZeneca resuming US testing of COVID-19 vaccine

FDA approves first COVID-19 drug: antiviral remdesivir

FDA approves first COVID-19 drug: antiviral remdesivir
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

FDA approves first COVID-19 drug: antiviral remdesivir

Here we go again: Trump, Biden reprise debate duel

Here we go again: Trump, Biden reprise debate duel
Instead, they're bracing for another show of vintage Trump, one in which he'll seek to be heard even in spite of his muted microphone.

Here we go again: Trump, Biden reprise debate duel

Getting ready for the gong show: Trump v. Biden II

Getting ready for the gong show: Trump v. Biden II
It's the sequel to last month's debate horror show between Donald Trump and Joe Biden, an invective-laced 90 minutes that laid bare the depths to which political discourse can sink in an American election year.

Getting ready for the gong show: Trump v. Biden II

US overdose deaths appear to rise amid coronavirus pandemic

US overdose deaths appear to rise amid coronavirus pandemic
Davidson lost his job. He started staying home alone in his apartment near Georgetown, Kentucky — depressed and yearning for his recovery support group that had stopped gathering in person, said his cousin Melanie Wyatt.

US overdose deaths appear to rise amid coronavirus pandemic

Pfizer: Mid-November earliest it can seek virus vaccine OK

Pfizer: Mid-November earliest it can seek virus vaccine OK
Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer: Mid-November earliest it can seek virus vaccine OK